Victoria Abadi-Ron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victoria Abadi-Ron has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alan Bonder
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
3 shared publications - Ana Marenco-Flores
Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
3 shared publications - Natalia Rojas Amaris
Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
3 shared publications - Behnam Saberi
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications - Esli Medina-Morales
Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO 63110, USA
2 shared publications - Fernando Munguia
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7928
Liver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study
Background: Fatigue and pruritus are common and disabling in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but their severity is not reliably explained by standard biochemical markers. Whether liver stiffness measured by transient elastography reflects these symptoms remains unclear. This study examined associations between liver stiffness and fatigue and pruritus in PBC and PSC, and between routine biochemical measures and symptom burden. Methods: This cross-sectional analysis included 107 patients (56 PBC, 51 PSC) from a prospective autoimmune liver disease registry. Fatigue was assessed with the CLDQ-29 fatigue domain and pruritus with the CLDQ-29 pruritus item or the itch visual analog scale. Multivariable linear and ordered logistic regression examined associations between liver stiffness and fatigue and pruritus, adjusted for disease type, age, and sex. Spearman correlations assessed associations between liver stiffness and clinical and laboratory variables, with Benjamini–Hochberg correction. Receiver operating characteristic analysis assessed discrimination. Results: Patients with PBC were older (59 vs. 51 years; p < 0.001) and more often female (96.4% vs. 56.9%; p < 0.001) than those with PSC. Liver stiffness (6.0 vs. 6.8 kPa; p = 0.101), fatigue scores, pruritus scores, and itch VAS were similar between groups. Liver stiffness was not associated with fatigue (β = 0.005; p = 0.835) or pruritus (OR = 0.97; p = 0.190) after adjustment; only age was associated with fatigue (β = 0.021; p = 0.020). Among laboratory measures, only ALP remained correlated with liver stiffness after correction (ρ = 0.309; adjusted p = 0.027). In PSC alone, higher liver stiffness was associated with worse pruritus (ρ = −0.37; p = 0.009), a finding not seen in PBC. Liver stiffness alone showed limited discrimination for fatigue (AUC 0.46) and pruritus (AUC 0.56); a model with disease type, age, and sex improved discrimination modestly for fatigue (AUC 0.60) but not for pruritus (AUC 0.57). Conclusions: Liver stiffness was not associated with fatigue or pruritus in the overall cohort of patients with PBC and PSC, and a possible association with pruritus in PSC needs confirmation. Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains an open question.
- 14 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7928
Open AccessLiver Stiffness, Patient-Reported Fatigue, and Pruritus in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Cross-Sectional Study
Background: Fatigue and pruritus are common and disabling in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but their severity is not reliably explained by standard biochemical markers. Whether liver stiffness measured by transient elastography reflects these symptoms remains unclear. This study examined associations between liver stiffness and fatigue and pruritus in PBC and PSC, and between routine biochemical measures and symptom burden. Methods: This cross-sectional analysis included 107 patients (56 PBC, 51 PSC) from a prospective autoimmune liver disease registry. Fatigue was assessed with the CLDQ-29 fatigue domain and pruritus with the CLDQ-29 pruritus item or the itch visual analog scale. Multivariable linear and ordered logistic regression examined associations between liver stiffness and fatigue and pruritus, adjusted for disease type, age, and sex. Spearman correlations assessed associations between liver stiffness and clinical and laboratory variables, with Benjamini–Hochberg correction. Receiver operating characteristic analysis assessed discrimination. Results: Patients with PBC were older (59 vs. 51 years; p < 0.001) and more often female (96.4% vs. 56.9%; p < 0.001) than those with PSC. Liver stiffness (6.0 vs. 6.8 kPa; p = 0.101), fatigue scores, pruritus scores, and itch VAS were similar between groups. Liver stiffness was not associated with fatigue (β = 0.005; p = 0.835) or pruritus (OR = 0.97; p = 0.190) after adjustment; only age was associated with fatigue (β = 0.021; p = 0.020). Among laboratory measures, only ALP remained correlated with liver stiffness after correction (ρ = 0.309; adjusted p = 0.027). In PSC alone, higher liver stiffness was associated with worse pruritus (ρ = −0.37; p = 0.009), a finding not seen in PBC. Liver stiffness alone showed limited discrimination for fatigue (AUC 0.46) and pruritus (AUC 0.56); a model with disease type, age, and sex improved discrimination modestly for fatigue (AUC 0.60) but not for pruritus (AUC 0.57). Conclusions: Liver stiffness was not associated with fatigue or pruritus in the overall cohort of patients with PBC and PSC, and a possible association with pruritus in PSC needs confirmation. Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains an open question.
- Open Access
- 19 June 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267
- 19 June 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Open AccessCurrent Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267
- Open Access
- 1 June 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102240
Longitudinal health-related quality of life and associated factors in autoimmune liver diseases
- 1 June 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102240
Open AccessLongitudinal health-related quality of life and associated factors in autoimmune liver diseases